Arkolith/Insider Trading/BEAM/Form 4

Evans John M.

CEO, DirectorBeam Therapeutics Inc. (BEAM) · full profile →Form 4 · filed Oct 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.2M
Net Open-Market Flow
-$1.2M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 2, 2025Sell(S)25K$24.63$616K987K
Oct 2, 2025Option exercise(M)25K$0.67$17K1.0M
Oct 1, 2025Sell(S)25K$24.51$613K987K
Oct 1, 2025Option exercise(M)25K$0.67$17K1.0M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 2, 2025Option exercise(M)25K—$019K
Oct 1, 2025Option exercise(M)25K—$044K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-230084) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML